Skip to main content

Table 3 The prevalence of antimicrobial drug resistance among Klebsiella pneumoniae isolates according to individual studies

From: Klebsiella pneumoniae: an increasing threat to public health

References

N

AMK

ATM

CAZ

CIP

COL

CTX

FEP

GEN

IPM

LVX

MEM

SXT

Liu et al. [30]

106

33

49

106

49

0

–

92

33

106

49

106

16

Tian et al. [39]

170

99

161

170

107

5

170

–

105

163

105

162

139

Zhao et al. [40]

63

48

61

62

59

–

–

58

50

62

56

63

–

Meng et al. [41]

142

45

89

78

67

–

–

81

69

–

60

–

42

Kim et al. [42]

579

–

139

–

141

–

–

–

–

–

–

–

131

Xu et al. [43]

30

16

–

29

26

–

28

24

–

–

23

–

–

Guo et al. [44]

8203

2568

4323

4077

4184

–

6005

2887

4651

468

–

476

5357

Dong et al. [29]

52

3

47

52

8

0

–

51

37

46

4

49

47

Cha et al. [45]

54

–

–

53

51

–

52

34

–

13

–

7

–

Mitra et al. [52]

55

45

50

–

52

–

53

–

52

–

–

29

49

Gautam et al. [53]

304

109

–

159

115

8

157

155

–

103

–

120

–

Mansury et al. [54]

38

6

–

–

–

–

19

–

16

6

–

4

–

Heidary et al. [55]

117

40

75

73

–

5

77

–

51

28

–

28

–

Ma et al. [56]

760

–

–

–

–

–

–

–

–

568

–

519

–

Sum

 

3012

4994

4859

4859

18

6561

3382

5064

1563

297

1563

5781

Rate (%)

 

40.8

73.3

75.7

59.8

2.9

79.2

72.6

58

65.6

54.1

62.7

58.2

  1. AMK, amikacin; ATM, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin; COL, colistin; CTX, cefotaxime; FEP, cefepime; GEN, gentamicin; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; SXT, trimethoprim-sulfamethoxazole